Kalaris Therapeutics
KLRS
32 hedge funds and large institutions have $111M invested in Kalaris Therapeutics in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 22 closing their positions.
353% more capital invested
Capital invested by funds: $24.6M → $111M (+$86.8M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
72.33% more ownership
Funds ownership: 1.87% → 74.19% (+72%)
8% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 13
38% less funds holding
Funds holding: 52 → 32 (-20)
91% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$112M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$2.79M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$1.8M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$99.4K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$43.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.13M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$279K |
| 3 |
Two Sigma Investments
New York
|
-$112K |
| 4 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$77.4K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$67.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Osaic Holdings
Scottsdale,
Arizona
| – | -$1.55K | -161 | Closed |
|
|
IA
52
IFP Advisors
Tampa,
Florida
| – | -$1.26K | -130 | Closed |
|
53
Citigroup
New York
| – | -$66 | -7 | Closed |
|
|
SS
54
SBI Securities
Tokyo,
Japan
| – | -$8 | -1 | Closed |
|
KLRS Hedge Fund Activity: Q1 2025 in Review
32 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q1 2025, worth a combined $111M — up 353% from $24.6M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of KLRS and 2 opened new positions — a net loss of 20 holders — while 13 trimmed existing stakes and 12 added.
The largest buyer was Samsara BioCapital, adding an estimated $112M. The largest seller was Millennium Management, cutting an estimated $1.13M.
- 32 institutional investors held Kalaris Therapeutics (KLRS) as of Q1 2025, down from 52 in Q4 2024.
- Funds reported $111M of Kalaris Therapeutics stock for Q1 2025, up 353% quarter-over-quarter.
- 2 funds opened new Kalaris Therapeutics positions in Q1 2025 and 22 closed out, a net change of -20 holders.
- The largest Kalaris Therapeutics buyer in Q1 2025 was Samsara BioCapital, an estimated $112M added.
- The largest Kalaris Therapeutics seller in Q1 2025 was Millennium Management, an estimated $1.13M sold.
Based on aggregated 13F filings for Q1 2025.